FLASCO - Clinical Oncology Series: Breast Cancer Updates - November 16, 2024

Orlando, FL US

Overview:

Delve into the current trends and future directions in breast cancer care, with a focus on personalized treatment plans, breakthrough research, and survivorship care. The FLASCO 2024 Clinical Oncology Series: Breast Cancer Updates program will feature presentations and discussions led by leading experts in the field, offering insights into the latest advancements in breast cancer diagnostics, treatment protocols, and patient management strategies. Attendees will gain a deeper understanding of innovative therapies and the impact of emerging technologies on patient outcomes. Additionally, the conference will address the psychosocial aspects of breast cancer survivorship, highlighting comprehensive care approaches that support patients' long-term well-being.

Learning Objectives:

 

  • Evolution of TNBC neo/adjuvant care

 

  • Recent advances in neo/adjuvant care of TNBC

 

  • The impact of antibody drug conjugates

 

  • Advancements in next generation sequencing and ctDNA

 

  • Adjuvant hormonal therapy options for curable breast cancer

 

  • Discussion of ovarian suppression in pre-menopausal early breast cancer

 

  • Update attendees on guidelines that inform treatment sequencing in HR+/HER2- MBC

 

  • Review safety and toxicity profiles of approved therapies

 

  • Review ongoing clinical trials that will potentially change treatment options and sequencing

 

  • Review safety and toxicity profiles of approved therapies

 

  • Understand the current therapies used for early stage HER2 positive breast cancer

 

  • Understand new therapeutic strategies currently in development for management of early stage HER2 positive breast cancer

 

  • To review the emerging trends for patients with metastatic HER2-positive breast cancer. 

 

  • Understand the phases of survivorship and the survivorship care models

 

  • Understand current challenges and opportunities in caring for breast cancer survivors

 

  • Anticipate and treat the most common side effects experienced by breast cancer patients (of any subtype)

 

  • Distinguish between evidence-based practices and potentially harmful "fringe" therapies to appropriately counsel sympotomatic patients

 

  • Describe the rationale and review clinical data for individualizing loco-regional therapy with neoadjuvant chemotherapy

 

  • Describe the rationale and review clinical data for individualizing adjuvant systemic therapy with neoadjuvant chemotherapy

 

  • Discuss the use of different fractionations for the treatment of early stage breast cancer

 

Course summary
Available credit: 
  • 5.50 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 5.50 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 5.50 credit.
Course opens: 
11/13/2024
Course expires: 
12/16/2024
Cost:
$0.00
Rating: 
0
Renaissance Orlando SeaWorld
6677 Sea Harbor Dr,
Orlando, FL 32821
United States

Disclosures

Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.

Faculty

Coy Heldermon, MD, PhD discloses advisory boards with Sanofi, Chiesi, consulting fees with Cardinal Health, and contracted research with Sanofi during the past 24 months.

Victoria Rizk, MD discloses speaker’s bureau with Lilly, Gilead, Springworks, advisory boards with Gilead, AstraZeneca, Novartis, Deciphera during the past 24 months.

Saranya Chumsri, MD discloses advisory boards with AstraZeneca, Daiichi, Sankyo, Immunomedics, Biotherano and consulting fee’s with Axiom, Cardinal Health, Cepton Strat and contracted research from Merck & Co., Pfizer, Salix Pharmaceuticals, Rebiotix Inc, Novartis during the past 24 months.

Lauren Carcas, MD discloses advisory boards with AstraZeneca and DSI, and consulting fee’s with AstraZeneca but these relationships have ended and contracted research All research is part of MCI and not 6

Reshma Mahtani, DO discloses advisory boards with AstraZeneca, Pfizer, Novartis, Daiichi, Lilly, consulting fee’s with Agendia, Amgen, AZ, Daiichi, Eisai, and contracted research with Gilead and AstraZeneca during the past 24 months.

Kristin Rojas, MD, FACS discloses advisory boards with Merck, Novartis and Consulting fee’s with Roche, and Diagnostic Solutions but these relationships have ended and speaker’s bureau with Pacira Pharmaceuticals during the past 24 months.

Eleftherios Mamounas, MD, MPH, FACS discloses speaker’s bureau with Merck, advisory boards with Merck, Genentech, Exact Sciences, Novartis, consulting fee’s with Tersera, GE Healthcare, Biotheranostics, Delphi and received funds from Moderna, Abbott Laboratories during the past 24 months.

Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

 

Available Credit

  • 5.50 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 5.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 5.50 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 5.50 credit.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above


Supported Phones & Tablets:

Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above